Zobrazeno 1 - 10
of 476
pro vyhledávání: '"Paul D. Miller"'
Publikováno v:
Bone Reports, Vol 11, Iss , Pp - (2019)
Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor signaling pathway that favors the stimulation of bone formation. Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates compar
Externí odkaz:
https://doaj.org/article/4eaf884eaedf4ed3bbf0d96ae1b0588f
Autor:
Paul D. Miller
Since 1898, the United States and the United Nations have deployed military force more than three dozen times in attempts to rebuild failed states. Currently there are more state-building campaigns in progress than at any time in the past century—i
Autor:
Ruban Dhaliwal, Didier Hans, Gary Hattersley, Bruce Mitlak, Lorraine A Fitzpatrick, Yamei Wang, Ann V Schwartz, Paul D Miller, Robert G Josse
Publikováno v:
JBMR Plus, Vol 5, Iss 2, Pp n/a-n/a (2021)
Externí odkaz:
https://doaj.org/article/e6eed3f93220457fbc078aa37679c19d
Autor:
E. Michael Lewiecki, John P. Bilezikian, Neil Binkley, Mary L. Bouxsein, Susan V. Bukata, David W. Dempster, Matthew T. Drake, Michael R. McClung, Paul D. Miller, Elisabeth Rosenthal, Laura L. Tosi
Publikováno v:
Journal of Clinical Densitometry. 25:649-667
The 22supnd/supAnnual Santa Fe Bone Symposium (SFBS) was a hybrid meeting held August 5-6, 2022, with in-person and virtual attendees. Altogether, over 400 individuals registered, a majority of whom attended in-person, representing many states in the
Autor:
Ruban Dhaliwal, Didier Hans, Gary Hattersley, Bruce Mitlak, Lorraine A Fitzpatrick, Yamei Wang, Ann V Schwartz, Paul D Miller, Robert G Josse
Publikováno v:
JBMR Plus, Vol 4, Iss 4, Pp n/a-n/a (2020)
ABSTRACT Type 2 diabetes mellitus (T2DM) increases fracture risk despite normal or increased BMD. Abaloparatide reduces fracture risk in patients with postmenopausal osteoporosis (PMO); however, its efficacy in women with T2DM is unknown. This post h
Externí odkaz:
https://doaj.org/article/fe38865d972b4df78653cb2dd78b4f71
Autor:
Ethel Siris, Michele McDermott, Nicola Pannacciulli, Paul D Miller, E Michael Lewiecki, Roland Chapurlat, Esteban Jódar‐Gimeno, Shuang Huang, John A Kanis
Publikováno v:
JBMR Plus, Vol 4, Iss 4, Pp n/a-n/a (2020)
ABSTRACT The 3‐year placebo‐controlled FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months) trial established the antifracture efficacy of denosumab in postmenopausal women with osteoporosis. The 7‐year open‐lab
Externí odkaz:
https://doaj.org/article/9f0cc4a05fd3401887b10a516bfcbe37
Autor:
Michael Pazianas, Paul D. Miller
Publikováno v:
Journal of Nephrology.
Autor:
Paul D Miller, Jonathan D Adachi, Ben‐Hur Albergaria, Angela M Cheung, Arkadi A Chines, Evelien Gielen, Bente L Langdahl, Akimitsu Miyauchi, Mary Oates, Ian R Reid, Norma Ruiz Santiago, Mark Vanderkelen, Zhenxun Wang, Zhigang Yu
Publikováno v:
Miller, P D, Adachi, J D, Albergaria, B H, Cheung, A M, Chines, A A, Gielen, E, Langdahl, B L, Miyauchi, A, Oates, M, Reid, I R, Santiago, N R, Vanderkelen, M, Wang, Z & Yu, Z 2022, ' Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease ', Journal of Bone and Mineral Research, vol. 37, no. 8, pp. 1437-1445 . https://doi.org/10.1002/jbmr.4563
Patients with osteoporosis and chronic kidney disease (CKD) are at increased risk of fracture and associated negative outcomes, including increased mortality. The present post hoc analysis of two randomized, multicenter, phase 3 clinical trials-Fract
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::275b6557dc439138ab47615df0fb7c5c
https://pure.au.dk/portal/da/publications/efficacy-and-safety-of-romosozumab-among-postmenopausal-women-with-osteoporosis-and-mildtomoderate-chronic-kidney-disease(6e1159b5-a9aa-415a-afe4-1b1285f1835b).html
https://pure.au.dk/portal/da/publications/efficacy-and-safety-of-romosozumab-among-postmenopausal-women-with-osteoporosis-and-mildtomoderate-chronic-kidney-disease(6e1159b5-a9aa-415a-afe4-1b1285f1835b).html
Autor:
Michael R. McClung, Micol S. Rothman, E. Michael Lewiecki, David A. Hanley, Steven T. Harris, Paul D. Miller, David L. Kendler
Publikováno v:
Postgraduate medicine. 134(6)
Reducing fracture risk is the objective of osteoporosis treatment. Bone-forming osteoporosis drugs increase bone mass, restore bone microarchitecture, and reduce fracture risk more effectively than oral bisphosphonates, providing strong justification
Publikováno v:
The New England journal of medicine. 386(15)